Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIT309 in Advanced Bone and Soft Tissue Sarcomas
NCT07052383Phase 1Suspended
- Sponsor
- Tcelltech GmbH
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DIT309 in osteosarcoma (OS) and soft tissue sarcoma (STS), sponsored by Tcelltech GmbH. Primary endpoints: Incidence of Dose Limiting Toxicity at 28 days, Incidence and severity of adverse events at 1 year and 1 more. Started Nov 2025; status: suspended.
02
Drugs
DIT309
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07052383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052383.